Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials
Gina L Mazza, Carolyn Mead-Harvey, John Mascarenhas, Abdulraheem Yacoub, Heidi E Kosiorek, Ronald Hoffman, Amylou C Dueck, Ruben A Mesa
Topics & Concepts
MedicinePolycythaemiaInternal medicineQuality of life (healthcare)Pegylated interferonClinical trialCancerOncologyAdverse effectAlpha interferonMEDLINEPediatricsThrombocytosisInterferon alfaDiseaseMyeloproliferative Neoplasms: Diagnosis and TreatmentCoagulation, Bradykinin, Polyphosphates, and AngioedemaPlatelet Disorders and Treatments